Literature DB >> 19737239

Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma.

H Hassanin1, S Serba, J Schmidt, A Märten.   

Abstract

Telomerase activity is over-expressed in nearly all pancreatic carcinomas, but not in chronic pancreatitis. Here, we investigated various protocols for expansion of telomerase-specific T cells for adoptive cell transfer and their use in a syngeneic pancreatic carcinoma mouse model. Telomerase-specific T cells were generated by stimulation of splenocytes from peptide-immunized donor mice with either interleukin (IL)-2, IL-15, artificial antigen-presenting cells, anti-signalling lymphocyte activation molecule (SLAM) microbeads or allogeneic dendritic cells in combination with a limited dilution assay. T cells were tested for antigen specificity in vitro and for anti-tumour activity in syngeneic mice with orthotopically implanted tumours pretreated with cyclophosphamide. The immune cells from recipients were immunophenotyped. During a period of 2 weeks, the expansion approach using IL-2 was very successful in generating a high number of telomerase-specific CD8(+) T cells without losing their function after adoptive cell transfer. Significantly slower tumour growth rate and less metastasis were observed after adoptively transferring telomerase specific CD8(+) T cells, expanded using IL-2. Further investigations showed that anti-tumour efficacy was associated with a significant shift from naive CD8(+) T cells to CD8(+) central memory T cells, as well as recruitment of a high number of dendritic cells. Remarkable amounts of telomerase-specific T cells were detectable in the tumour. Generation of telomerase-specific T cells is feasible, whereat IL-2-based protocols seemed to be most effective and efficient. Antigen-specific T cells showed significant cytotoxic activity in a syngeneic, orthotopic mouse model, whereas central memory T cells but not effector memory T cells appear to be of high importance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737239      PMCID: PMC2759067          DOI: 10.1111/j.1365-2249.2009.03935.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

Review 2.  Telomerase inhibitors.

Authors:  L K White; W E Wright; J W Shay
Journal:  Trends Biotechnol       Date:  2001-03       Impact factor: 19.536

Review 3.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.

Authors:  T A Waldmann; S Dubois; Y Tagaya
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

4.  Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma.

Authors:  S Serba; J Schmidt; N Wentzensen; E Ryschich; A Märten
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

5.  Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.

Authors:  J Arai; M Yasukawa; H Ohminami; M Kakimoto; A Hasegawa; S Fujita
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

6.  Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.

Authors:  A Heiser; M A Maurice; D R Yancey; D M Coleman; P Dahm; J Vieweg
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

7.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.

Authors:  E M Jaffee; R H Hruban; B Biedrzycki; D Laheru; K Schepers; P R Sauter; M Goemann; J Coleman; L Grochow; R C Donehower; K D Lillemoe; S O'Reilly; R A Abrams; D M Pardoll; J L Cameron; C J Yeo
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

8.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

Authors:  S K Nair; A Heiser; D Boczkowski; A Majumdar; M Naoe; J S Lebkowski; J Vieweg; E Gilboa
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

9.  Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.

Authors:  M Ayyoub; M Migliaccio; P Guillaume; D Liénard; J C Cerottini; P Romero; F Lévy; D E Speiser; D Valmori
Journal:  Eur J Immunol       Date:  2001-09       Impact factor: 5.532

10.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.

Authors:  B Minev; J Hipp; H Firat; J D Schmidt; P Langlade-Demoyen; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

View more
  3 in total

1.  BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity.

Authors:  Kimberly Mayes; Suehyb G Alkhatib; Kristen Peterson; Aiman Alhazmi; Carolyn Song; Vivian Chan; Tana Blevins; Mark Roberts; Catherine I Dumur; Xiang-Yang Wang; Joseph W Landry
Journal:  Cancer Res       Date:  2016-09-20       Impact factor: 12.701

Review 2.  Emerging trends in the immunotherapy of pancreatic cancer.

Authors:  Kasturi Banerjee; Sushil Kumar; Kathleen A Ross; Shailendra Gautam; Brittany Poelaert; Mohd Wasim Nasser; Abhijit Aithal; Rakesh Bhatia; Michael J Wannemuehler; Balaji Narasimhan; Joyce C Solheim; Surinder K Batra; Maneesh Jain
Journal:  Cancer Lett       Date:  2017-12-12       Impact factor: 8.679

Review 3.  The dark side of immunotherapy: pancreatic cancer.

Authors:  Gianluca Mucciolo; Cecilia Roux; Alessandro Scagliotti; Silvia Brugiapaglia; Francesco Novelli; Paola Cappello
Journal:  Cancer Drug Resist       Date:  2020-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.